Oxybutynin is linked to a meaningful increase in dementia risk, particularly with long-term use. A large 2024 study published in BMJ Medicine found that people who took oxybutynin for the equivalent of one to three years had a 31% higher risk of dementia compared to non-users. Those who took it for more than three years had a 28% higher risk. The connection is strong enough that the American Geriatrics Society explicitly recommends avoiding oxybutynin in adults over 65.
How Oxybutynin Affects the Brain
Oxybutynin is prescribed for overactive bladder. It works by blocking a chemical messenger called acetylcholine from reaching receptors on bladder muscle, which reduces urgency and frequency. The problem is that acetylcholine also plays a central role in memory, attention, and learning. Oxybutynin doesn’t just block acetylcholine in the bladder. It blocks it throughout the body, including the brain.
What makes oxybutynin particularly concerning compared to some other medications is its chemical structure. It’s a tertiary amine, meaning it’s small, fat-soluble, and carries a neutral charge. These are exactly the properties that allow a drug to slip easily across the blood-brain barrier. Once inside the brain, oxybutynin blocks the same acetylcholine receptors (M1, M2, and M3) that are critical for cognitive function. This is the same neurotransmitter system that deteriorates in Alzheimer’s disease, which is why Alzheimer’s drugs work by doing the opposite: boosting acetylcholine levels.
What the Research Shows About Dementia Risk
The clearest data comes from a nested case-control study in BMJ Medicine that looked at adults aged 55 and older. Researchers tracked cumulative oxybutynin use using “total standardized daily doses,” essentially counting how many days’ worth of medication a person had taken over a 13-year window. The risk of dementia climbed in a dose-dependent pattern:
- 1 to 90 days of use: 4% increased risk
- 91 to 365 days: 14% increased risk
- 1 to 3 years: 31% increased risk
- More than 3 years: 28% increased risk
The slight dip at the highest exposure level likely reflects statistical variability rather than a true decrease in risk. The overall pattern is clear: more oxybutynin use correlates with higher dementia risk. A separate study using Canadian health data found that users of anticholinergic bladder medications as a class had a 23% higher risk of dementia compared to people who took mirabegron, a newer bladder drug that works through a completely different mechanism.
These are observational studies, so they can’t prove that oxybutynin directly causes dementia. It’s possible that people with early, undetected cognitive decline are more likely to develop bladder problems, creating a statistical link that isn’t truly causal. But the dose-response relationship, the biological plausibility through acetylcholine blockade, and the consistency across multiple studies make the association difficult to dismiss.
Short-Term Cognitive Effects
Beyond the long-term dementia question, oxybutynin can cause noticeable cognitive side effects while you’re taking it. These include confusion, difficulty concentrating, memory lapses, and an increased risk of delirium, especially in older adults. The 2023 Beers Criteria, which is the standard reference for medication safety in older adults, flags cumulative anticholinergic exposure as a risk factor for falls, delirium, and dementia “even in younger adults.”
Whether these short-term effects reverse after stopping the drug is surprisingly unclear. A systematic review found only four studies that examined cognitive recovery after discontinuing anticholinergic medications. The two cohort studies showed some improvement in cognitive performance after stopping, but the two clinical trials did not. Researchers concluded that the question remains poorly understood and needs longer follow-up periods to answer properly. In practical terms, some people may recover cognitive sharpness after stopping oxybutynin, but there’s no guarantee, and longer use may carry more lasting effects.
Why Oxybutynin Stands Out Among Bladder Drugs
Not all overactive bladder medications carry the same level of concern. Oxybutynin is considered one of the worst offenders because of how easily it enters the brain. Other anticholinergic bladder drugs like tolterodine, solifenacin, and darifenacin also block acetylcholine, but some have slightly less ability to cross the blood-brain barrier or are more selective about which receptors they target. That said, the entire class carries some degree of cognitive risk.
Mirabegron works through a completely different pathway. It’s a beta-3 agonist, meaning it relaxes the bladder muscle without interfering with acetylcholine at all. A small pilot study switched 20 older adults with spinal cord injuries from anticholinergic bladder medications (mostly oxybutynin and tolterodine) to mirabegron. After six months, participants showed significant improvements in immediate recall, delayed recall, and executive function, along with better urinary symptom control. While this was a small study, it aligns with the broader evidence that mirabegron doesn’t carry the same cognitive burden.
What the Guidelines Recommend
The 2023 American Geriatrics Society Beers Criteria lists oxybutynin as a drug to avoid in older adults. It falls under two separate categories on the list: as a gastrointestinal antispasmodic with strong anticholinergic activity and as an antimuscarinic for urinary incontinence. Both carry a “strong” recommendation to avoid, with the rationale that oxybutynin is “highly anticholinergic” with “uncertain effectiveness.” The guidelines also emphasize that clinicians should consider total anticholinergic burden during medication reviews, meaning oxybutynin’s risk compounds if you’re also taking other anticholinergic drugs like certain antihistamines, antidepressants, or sleep aids.
For people currently taking oxybutynin, especially those over 55, the evidence supports having a conversation about alternatives. Non-drug approaches like pelvic floor exercises and bladder training are first-line treatments for overactive bladder and carry zero cognitive risk. If medication is needed, mirabegron offers a pharmacological option without the anticholinergic effects that drive dementia concerns. Stopping oxybutynin abruptly is generally safe, but switching medications should be coordinated with a prescriber to ensure bladder symptoms remain controlled.